Polyrizon Ltd. (Nasdaq: PLRZ) reported that its PL‑14 Allergy Blocker hydrogel spray achieved a statistically significant reduction in house dust mite allergen (Der p 1) transfer in a new in‑vitro Transwell permeability study. Compared with hydroxypropyl methylcellulose (HPMC), the standard nasal barrier comparator, PL‑14 reduced Der p 1 concentrations at every tested time point—1, 2, 4, 6, and 24 hours—with p‑values of 0.0042 or lower. At 1 hour, mean Der p 1 levels were 20.6 ng for PL‑14 versus 1,354.4 ng for HPMC; at 24 hours, the levels were 141.2 ng for PL‑14 compared with 5,201.2 ng for HPMC.
The data demonstrate that PL‑14 forms a robust intranasal hydrogel barrier that physically blocks allergen penetration, a mechanism distinct from the pharmacologic action of antihistamines or corticosteroids. The magnitude of the reduction—over 90 % lower allergen penetration at 24 hours—underscores the platform’s potential to provide a preventive solution for allergic rhinitis, a condition affecting more than 400 million people worldwide. By outperforming HPMC, the study validates Polyrizon’s proprietary Capture‑and‑Contain hydrogel technology and strengthens the case for advancing PL‑14 into human trials.
Polyrizon remains a development‑stage company with no revenue and significant net losses, but it maintains a debt‑free balance sheet and robust liquidity. The pre‑clinical success reinforces the company’s pipeline, which also includes PL‑16 Viral Blocker and a naloxone hydrogel program. The validation of PL‑14’s barrier function is a key milestone that can attract future funding and accelerate the company’s path to regulatory submission.
CEO Tomer Izraeli said the results “reinforce our belief that PL‑14 can form an effective intranasal hydrogel barrier capable of reducing allergen exposure to nasal tissue.” He added that the data support the company’s strategy to move PL‑14 into Phase 1 trials and to pursue regulatory approval for a preventive allergy product. Polyrizon plans to initiate clinical studies in the second half of 2026, contingent on securing additional capital and completing pre‑clinical safety work.
The strong pre‑clinical data are expected to enhance investor confidence in Polyrizon’s technology platform and pipeline. The company’s next steps include finalizing the clinical trial design, filing an Investigational New Drug application, and securing the necessary funding to support the clinical program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.